Press Release: AFTD Announces Biomarkers Award Recipients
The current lack of biomarkers for FTD contributes to diagnostic delays and errors, and hinders the assessment of drug effectiveness in clinical trials. To address this unmet need, the FTD Biomarkers Initiative, launched in 2016 by AFTD and made possible by a generous donation from the Samuel I. Newhouse Foundation, will provide $5 million over a 5-year period to support the discovery and development of FTD biomarkers.
AFTD is proud to announce the recipients of the 2016 FTD Biomarkers Initiative awards, among them SyNergy member Dr. Christian Haass:
Randall Bateman, MD, Washington University, St. Louis.
Christian Haass, PhD, Ludwig Maximilian University & the German Centre for Neurodegenerative Diseases, Munich.
Leonard Petrucelli, PhD, Mayo Clinic, Jacksonville.
Jonathan Rohrer, MRCP, PhD, University College London, UK.
Judith Steen, PhD, Boston Children's Hospital.